IRIS
TIRIBELLI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.580
AS - Asia 5.875
EU - Europa 3.803
SA - Sud America 1.195
AF - Africa 126
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 10
Totale 24.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.313
SG - Singapore 2.689
CN - Cina 1.232
BR - Brasile 952
UA - Ucraina 886
HK - Hong Kong 590
VN - Vietnam 525
DE - Germania 521
IT - Italia 450
FR - Francia 419
FI - Finlandia 396
RU - Federazione Russa 291
CA - Canada 183
SE - Svezia 183
IE - Irlanda 176
IN - India 167
TR - Turchia 142
GB - Regno Unito 134
AR - Argentina 107
NL - Olanda 105
BD - Bangladesh 95
KR - Corea 71
JP - Giappone 57
IQ - Iraq 50
ID - Indonesia 49
PL - Polonia 49
ES - Italia 42
AT - Austria 38
AU - Australia 38
PK - Pakistan 36
MX - Messico 33
ZA - Sudafrica 33
CO - Colombia 31
EC - Ecuador 30
MA - Marocco 24
IR - Iran 23
UZ - Uzbekistan 18
BE - Belgio 17
CL - Cile 17
SA - Arabia Saudita 17
VE - Venezuela 17
EG - Egitto 16
GR - Grecia 16
CZ - Repubblica Ceca 15
KE - Kenya 14
PY - Paraguay 14
JO - Giordania 13
PE - Perù 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 10
JM - Giamaica 10
PH - Filippine 9
UY - Uruguay 9
AZ - Azerbaigian 8
CR - Costa Rica 8
KZ - Kazakistan 8
TG - Togo 8
AL - Albania 7
EU - Europa 7
LB - Libano 7
LT - Lituania 7
OM - Oman 7
ET - Etiopia 6
HU - Ungheria 6
PA - Panama 6
TH - Thailandia 6
BG - Bulgaria 5
BH - Bahrain 5
BO - Bolivia 5
HN - Honduras 5
KG - Kirghizistan 5
LY - Libia 5
NI - Nicaragua 5
NP - Nepal 5
AO - Angola 4
IL - Israele 4
MY - Malesia 4
RO - Romania 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
LU - Lussemburgo 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
DZ - Algeria 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
MD - Moldavia 2
NG - Nigeria 2
QA - Qatar 2
Totale 24.600
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.487
Fairfield 1.407
Singapore 1.038
Ashburn 975
Houston 920
Ann Arbor 880
Beijing 605
Hong Kong 583
Jacksonville 583
Seattle 582
San Jose 558
Chandler 551
Wilmington 495
Cambridge 476
Dearborn 397
Council Bluffs 305
Boardman 266
Lauterbourg 193
Princeton 181
Dublin 174
Los Angeles 164
Dallas 158
Ho Chi Minh City 149
Buffalo 112
Dong Ket 110
Udine 107
Helsinki 104
Izmir 99
New York 90
Hanoi 88
Munich 85
San Diego 83
Hefei 78
São Paulo 72
Santa Clara 71
Seoul 65
Tokyo 57
Amsterdam 55
Ogden 54
Redondo Beach 53
The Dalles 51
Des Moines 47
Warsaw 44
Calgary 39
Frankfurt am Main 39
Orem 38
Boston 37
Norwalk 37
Phoenix 37
Nanjing 35
Trieste 35
Turku 35
Ottawa 32
Stanford 30
Melbourne 29
Brooklyn 28
Chennai 28
Montreal 28
Pittsburgh 28
Toronto 28
Nuremberg 27
Mumbai 26
Chevy Chase 25
Rio de Janeiro 25
Milan 23
Philadelphia 23
Salvador 23
Atlanta 22
Guangzhou 22
Kunming 21
Hangzhou 20
Lutz 20
Belo Horizonte 19
Chicago 19
Porto Alegre 19
Vienna 19
Rome 18
Stockholm 18
Tashkent 18
Baghdad 17
Cardiff 16
Istanbul 16
Johannesburg 16
London 16
Paris 16
Redmond 16
Vancouver 16
Washington 16
San Francisco 15
Brussels 14
Da Nang 14
Lappeenranta 14
Lille 14
New Delhi 14
Denver 13
Duino-Aurisina 13
Haiphong 13
Santa Maria 13
Shanghai 13
Amman 12
Totale 15.929
Salva come PNG Salva come JPEG
Nome #
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 772
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 226
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology 222
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 210
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 208
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. 207
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 205
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 201
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 192
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 187
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 184
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 182
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 181
Histone post-translational modifications associated to BAALC expression in leukemic cells. 180
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 179
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 179
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 178
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. 178
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 174
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 173
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 173
All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines 172
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 169
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 164
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors 163
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 162
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 161
Erratum: Functional regulation of the Apurinic/apyrimidinic endonuclease APE1 by Nucleophosmin (NPM1): Impact on tumor biology 158
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 158
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 156
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 155
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 154
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 154
Unexpected phenotype of a typical NPM1 mutant 153
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 153
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 150
Evaluation of residual CD34+ Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy 150
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 149
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 149
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 149
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 149
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 147
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 147
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 146
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 146
ABCB1 (PGP) and ABCG (BCRP) proteins are independent prognostic factors for complete remissione and relapse risk, respectively in normal karyotype adult de novo acute myeloid leukemia. 146
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 146
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. 146
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. 144
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 144
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 144
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 143
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. 142
Epstein-Barr virus (EBV) reactivation in a patient treated with ATG for severe aplastic anemia 141
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 140
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 140
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 140
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 140
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia 139
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 139
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia 139
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. 139
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data 138
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients 137
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia 136
Prognostic factors anad expression of multidrug-resistance related proteins in 36 patients with acute promyelocytic leukemia. 135
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. 135
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 135
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 134
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 134
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 133
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 132
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 132
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 131
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib 131
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? 131
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 130
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 129
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase 128
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 128
How could patient reported outcomes improve patient management in chronic myeloid leukemia? 127
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 127
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 127
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 126
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 126
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicinee—Results from the Italian ‘Back to Life’ project 126
A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 420 CASES 125
The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. 125
GVHD and cyclosporien levels in blood in different moments after allogeneic bone marrow transplantation: an open question? 124
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 124
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience 123
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 123
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 121
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 121
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 120
The significance of early warning in chronic myeloid leukemia 119
The efficacy of imatinib mesylate in patients with the FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study 118
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. 118
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. 118
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 118
Totale 15.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.167
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.348 64 145 51 65 23 66 78 60 16 226 325 229
2022/20231.338 199 80 8 156 136 391 6 108 170 24 43 17
2023/2024474 65 48 11 24 52 38 8 49 76 38 24 41
2024/20253.547 79 251 113 141 125 141 235 223 361 331 542 1.005
2025/20267.971 608 773 646 800 1.036 622 883 292 627 760 477 447
2026/2027155 155 0 0 0 0 0 0 0 0 0 0 0
Totale 25.158